Innovative and proprietary science and technologies

Please click on the links below to find out more about the science and technologies that underpin UCB's R&D.

Science/Technology	Description
Powerful proprietary antibody technology	UCB SLAM is creating high affinity antibodies against molecular targets involved in disease. It is the start point for UCB’s antibody-based drugs.
Making antibodies work in the therapeutic environment	UCB’s antibody technology includes humanising antibodies for safety and efficacy, antibody protein expression and antibody protein science.
Gene-to-Drug research, proprietary genetic mapping and genomic sequencing of the target protein	UCB’s Gene-to-drug research has led to the discovery of the sclerostin antibody, a neutralising antibody that increases bone deposition and strength in bone diseases.
Synergy between biologicals and small molecule research	UCB’s A2Hit™ Antibody to Hit technology uses information from antibodies to design new small molecule drugs.
Screening compounds to find the right small molecules to develop into drugs	UCB’s Hit Discovery from the Chemical Universe uses virtual and fragment screening.
Advanced modelling, simulation and data visualisation techniques to develop hits into effective new drugs.	UCB uses CADD: Computer Assisted Drug Discovery that includes structure-based drug design.
Key drug discovery techniques	UCB purifies drugs using multi-column chromatography.
Proprietary scientific platform	UCB’s pioneering SV2A research has led to the discovery of a new way to treat epilepsy and potential for other CNS conditions.
Genomics technology and genetic information	Genomics – UCB is using advanced technology in discovery research for insight into a drug’s mechanism of action to develop more effective, safer drugs and for the identification of early biomarkers.